Rheumatoid Arthritis
News
Retreatment With High-Dose Rituximab Reduced DAS28 Levels
Major Finding: In patients with rheumatoid arthritis, initial treatment with rituximab 500 mg x 2 or 1,000 mg x 2 led to comparable clinical...
News
Two Biomarkers Predict Response to Rituximab in RA
Major Finding: Continued response to rituximab in patients with RA after 6 months of therapy can be predicted by B-cell repopulation and...
News
Exploring the Safety of the New Subcutaneous Abatacept
Major Finding: Abatacept administered as a weekly subcutaneous injection has a safety profile similar to that of abatacept administered as a...
News
RA Remission Rates With Tocilizumab Monotherapy Equals Combination TX With Methotrexate*
Major Finding: Quality of life measures, including the HAQ-DI and the DAS28, were comparable for patients who received tocilizumab, either with...
News
Seropositivity Predicts Good Response to Rituximab in RA
Major Finding: Patients with rheumatoid arthritis who are seropositive achieve significantly greater reductions in DAS28 at 6 months than do those...
News
Rituximab-Induced Low IgG Linked to Infections
Findings: A twofold increased risk of serious infections was noted in RA patients with low IgG levels following rituximab treatment. Data source:...
News
RA: Adalimumab, MTX Induction Yields Sustained Response
Major Finding: DAS28 was reduced from 6.2 to 3.0 after a 24-week induction phase in 87 RA patients randomized to receive combination therapy,...
News
Heart of a Lion: Rheumatologist Holds Fast to His Charitable Plans
Conference Coverage
HAQ May Predict Which RA Patients Can Stop TNF-Inhibitors
Major Finding: A majority (81%) of patients in the adalimumab withdrawal group achieved DAS28 of less than 3.2, compared with 91% of those in the...
News
Shingles Vaccine Safe for Adults on Biologics
Major Finding: The incidence rate for shingles at least 42 days after vaccination was 8 cases/1,000 person-years among vaccinated adults on a...
News
TEAR Trial Validates Methotrexate First Strategy for Early RA
Major Finding: Of 379 patients who received methotrexate monotherapy, 28% achieved a DAS28 below 3.2.